anti-CD70 monoclonal antibody SEA-CD70

A humanized, nonfucosylated monoclonal antibody directed against the human CD70 antigen, with potential immunomodulatory and antineoplastic activities. Upon administration, anti-CD70 monoclonal antibody sugar-engineered antibody (SEA)-CD70 selectivity targets and binds to the extracellular domain of CD70, which blocks CD70-mediated signaling. This may inhibit cellular proliferation and survival of CD70-expressing tumor cells, and may modulate the immune system to inhibit inflammatory signals and increase antigen-specific T-cell responses in the tumor microenvironment (TME). In addition, SEA-CD70 induces antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) against CD70-expressing tumor cells. CD70, a member of the tumor necrosis factor (TNF) family, is aberrantly expressed on malignant myeloid blasts while absent from healthy hematopoietic progenitor cells.